Granules India Raises ₹1,762 Cr Via Preferential Allotment; Share Capital Upscaled

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Granules India Raises ₹1,762 Cr Via Preferential Allotment; Share Capital Upscaled
Overview

Granules India's board approved a significant preferential allotment of 2.50 crore warrants and 51.28 lakh equity shares, potentially raising up to ₹1,762.5 crore. The issuance aims to bolster the company's capital structure and fund growth initiatives. This move, however, also leads to a potential dilution for existing shareholders.

Granules India Secures ₹1,762 Crore Via Preferential Allotment

Granules India is set to receive up to ₹1,762.5 crore through a preferential allotment of 2.50 crore warrants and 51.28 lakh equity shares at ₹585 per share.
The capital infusion aims to strengthen the company's financial position and support future growth.

Reader Takeaway: Capital infusion bolsters balance sheet; potential dilution from warrants is a key watchpoint.

What just happened (today’s filing)

Granules India's committee of directors has approved a significant preferential allotment of 2.50 crore warrants and 51.28 lakh equity shares.
The issue price for both warrants and equity shares has been fixed at ₹585 per unit.

The allotment of 51.28 lakh equity shares to the non-promoter category has already raised ₹300 crore.
Additionally, a partial amount of ₹365.625 crore has been received for the 2.50 crore warrants, which are convertible into equity shares within 18 months.

This transaction increases the company's paid-up equity share capital from ₹24.27 crore to ₹24.78 crore.
The total potential capital to be raised stands at approximately ₹1,762.5 crore (₹300 crore from shares + ₹1,462.5 crore from warrants).

Why this matters

This capital infusion provides Granules India with substantial financial resources.
It is expected to strengthen the company's balance sheet and enhance its financial flexibility for strategic initiatives.

The issuance of equity shares and potential conversion of warrants will alter the company's capital structure.
This could lead to dilution for existing shareholders, impacting their percentage ownership.

The backstory (grounded)

Granules India recently reported robust financial performance, with Q3 FY26 marking a record quarter. Net sales reached ₹1,387.94 crore, a 22% year-on-year increase, while net profit surged 27.73% to ₹150.21 crore. This strong operational momentum underscores the company's growth trajectory.

In a strategic move in 2025, Granules India expanded its capabilities by acquiring Senn Chemicals AG, a Swiss-based CDMO, aiming to bolster its presence in the peptides segment.

What changes now

  • The company's equity base will expand, potentially improving its debt-to-equity ratio if funds are used to reduce debt.
  • Existing shareholders will experience a dilution in their ownership percentage upon the conversion of warrants into shares.
  • The raised capital is expected to fuel expansion plans, research and development, or debt reduction.
  • The company's financial leverage and capital structure will be significantly altered.

Risks to watch

Granules India has faced scrutiny from the US Food and Drug Administration (USFDA).
In March 2025, the USFDA issued a warning letter citing significant lapses at its Telangana plant, including contamination and poor maintenance practices.

Earlier inspections in September 2024 and December 2025 at various facilities also resulted in observations related to procedural requirements and good manufacturing practices.

While this preferential allotment strengthens the balance sheet, sustained improvement in quality compliance and addressing regulatory observations remain critical for long-term operational stability.

Peer comparison

Granules India operates in a competitive landscape alongside major pharmaceutical players.
Its peers include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., and Lupin Ltd., all of which are significant global API manufacturers with strong R&D and manufacturing footprints.

While peers often engage in strategic acquisitions and capacity expansions, Granules India's current move focuses on capital enhancement through equity issuance, complementing its growth strategy.

Context metrics (time-bound)

  • The preferential issue aims to raise up to approximately ₹1,762.5 crore in Q4 FY26.
  • Warrants are convertible into equity shares within 18 months from the allotment date.
  • The company's paid-up equity share capital increased from ₹24.27 crore to ₹24.78 crore following the allotment.

What to track next

  • Monitor the conversion status of the 2.50 crore warrants into equity shares over the next 18 months.
  • Track the company's progress in addressing USFDA observations and maintaining quality compliance across its facilities.
  • Observe how the raised capital is deployed to support business growth and strategic objectives.
  • Evaluate the impact of potential share dilution on earnings per share (EPS) and shareholder value.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.